Ausgabe 4/2005
Inhalt (13 Artikel)
Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid
Stefan R. Vink, Jan H. M. Schellens, Wim J. van Blitterswijk, Marcel Verheij
Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP
Beata Kosmider, Izabela Wojcik, Regina Osiecka, Jacek Bartkowiak, Elzbieta Zyner, Justyn Ochocki, Pawel Liberski
A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines
Kongming Wu, Mark D’Amico, Chenguang Wang, Chris Albanese, Richard G. Pestell, Sridhar Mani
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
Kim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon
Human metabolism of [14C]indisulam following i.v. infusion in cancer patients
Jan-Hendrik Beumer, Michel J. X. Hillebrand, Dick Pluim, Hilde Rosing, Karen Foley, S. Murray Yule, Jan H. M. Schellens, Jos H. Beijnen
Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer
Takahiko Sugiura, Yutaka Ariyoshi, Shunichi Negoro, Shinichiro Nakamura, Harumichi Ikegami, Minoru Takada, Takashi Yana, Masahiro Fukuoka
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors
Moritz N. Wente, Jörg Kleeff, Markus W. Büchler, Jantien Wanders, Peter Cheverton, Stephen Langman, Helmut Friess
Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study
Peter Schmid, Bernd Flath, Konstantin Akrivakis, Volker Heilmann, Hans-Günther Mergenthaler, Orhan Sezer, Rolf Kreienberg, Kurt Possinger
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Susan M. Chang, Patrick Wen, Timothy Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Lisa De Angelis, Jeffrey Raizer, Kenneth Hess, Ken Aldape, Kathleen R. Lamborn, John Kuhn, Janet Dancey, Michael D. Prados
BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)
R.-D. Hofheinz, C. Porta, G. Hartung, A. Santoro, A.-R. Hanauske, K. Kutz, A. Stern, P. Barbieri, E. Verdi, R. Hehlmann, A. Hochhaus
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
Nicolas Tsavaris, Christos Kosmas, Helias Skopelitis, Panagiotis Gouveris, Petros Kopteridis, Dioynissis Loukeris, Frantzeska Sigala, Alexandra Zorbala-Sypsa, Evangelos Felekouras, Efstathios Papalambros